This white paper assesses Singapore’s readiness to scale radioligand therapy (RLT) as a standard-of-care treatment, focusing on PSMA-targeted therapies for metastatic prostate cancer. It evaluates disease burden, clinical evidence, infrastructure capacity, workforce availability, regulatory pathways, and funding mechanisms. The paper identifies gaps in awareness, diagnostic access, specialist staffing, and reimbursement that limit adoption. Drawing on global case studies, it proposes solutions to strengthen referral pathways, expand nuclear medicine capacity, and improve financing. The paper concludes that coordinated national action can position Singapore as a regional leader in precision oncology.

Join for free to read